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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Danish lan-
guage. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre 
was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation 
phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling 
effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability and construct validity (convergent 
and discriminant validity). A total of 303 JIA patients (7.9% systemic, 35% oligoarticular, 22.1% RF negative polyarthritis, 
35% other categories) and 99 healthy children, were enrolled in three centres. The JAMAR components discriminated well 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
Danish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Danish parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/
patient-reported outcomes in JIA, including overall well-
being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with ill-
ness outcome.
This project was part of a larger multinational study 
conducted by the Paediatric Rheumatology International 
Trials Organisation (PRINTO) [2] aimed to evaluate the 
epidemiology, outcome and treatment of childhood arthri-
tis (EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adap-
tation and validation of the parent and patient versions of 
the JAMAR in the Danish language.
Rheumatology
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Materials and methods
The methodology employed has been described in detail 
in the introductory paper of the supplement [4]. In brief, 
it was a cross-sectional study of JIA children, classified 
according to the ILAR criteria [5, 6] and enrolled from 
January 2012 to February 2013. Children were recruited 
after Ethics Committee approval and consent from at least 
one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-culturally adapted 
in a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addi-
tion of the parent assessment of disease activity and pain 
by the Spearman’s correlation coefficients (r) [17] and the 
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discriminant validity, which assesses whether the JAMAR 
discriminates between the different JIA categories and 
healthy children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Danish parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Danish JAMAR was fully cross-culturally adapted from 
the standard English version with two forward and two back-
ward translations with a concordance for 105/123 transla-
tion lines (85.4%) for the parent version and 107/120 lines 
(89.2%) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the ten parents tested 
(median = 100%; range 80–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%). The 
text of the parent JAMAR was unmodified after the probe 
technique; even if not required by the methodology, the com-
ments of the two children who did not understand line 107 of 
the child JAMAR were considered appropriate and the line 
was modified accordingly.
Demographic and clinical characteristics 
of the subjects
A total of 303 JIA patients and 99 healthy children (total of 
402 subjects) were enrolled at three paediatric rheumatol-
ogy centres.
In the 303 JIA subjects, the JIA categories were 7.9% 
with systemic arthritis, 35% with oligoarthritis, 22.1% with 
RF-negative polyarthritis, 5.6% with RF-positive polyar-
thritis, 6.3% with psoriatic arthritis, 12.9% with enthesitis-
related arthritis and 10.2% with undifferentiated arthritis 
(Table 1).
A total of 343/402 (85.3%) subjects had the parent ver-
sion of the JAMAR completed by a parent (267 from parents 
of JIA patients and 76 from parents of healthy children). The 
JAMAR was completed by 281/343 (81.9%) mothers and 
62/343 (18.1%) fathers. The child version of the JAMAR 
was completed by 357/402 (88.8%) children aged 7.2 or 
older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for item 8, whereas a reduced number of response 
choices was used for PF items 2, 9, 11, 12, 13 and 14.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL item 1 (data not shown). The median 
number of items marked as not applicable was 2% (0–6%) 
for the PF and 7.5% (1–9%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 84.3% (60.7–95.5%) for the 
PF items, 50.6% (22.1–79.0%) for the HRQoL-PhH items, 
and 61.8% (49.8–79.4%) for the HRQoL-PsH items. The 
median ceiling effect was 0.4% (0–1.9%) for the PF items, 
4.1% (0.7–10.5%) for the HRQoL-PhH items, and 0.7% 
(0–3.7%) for the HRQoL-PsH items. The median floor effect 
was 25.1% for the pain VAS, 25.1% for the disease activity 
VAS and 23.6% for the well-being VAS. The median ceiling 
effect was 0% for the pain VAS, 0.7% for the disease activity 
VAS and 0.7% for the well-being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson’s items–scale correlations corrected for overlap 
were roughly equivalent for items within a scale for 87% of 
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 303 JIA patients
Data related to the JAMAR refers to the 267 JIA patients and to the 76 healthy subjects for whom the questionnaire has been completed by the 
parents. p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001 #p < 0.0001
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS Visual Analogue 
Scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
Systemic Oligoarthritis RF − polyar-
thritis
RF + polyar-
thritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 24 N = 106 N = 67 N = 17 N = 19 N = 39 N = 31 N = 303 N = 99
Female 11 (45.8%) 80 (75.5%) 57 (85.1%) 17 (100%) 16 (84.2%) 21 (53.8%) 20 (64.5%) 222 (73.3%)# 50 (50.5%)#
Age at visit 13.8 (10.5–
15.3)
12.4 
(9.5–14.8)
12.8 
(9.9–14.6)
14.2 (13.1–
15.5)
16.8 
(11.4–18)
15.4 (14.1–
17.7)
11 (6.2–14.2) 13.2 (10.1–
15.6)#
12 (9.8–15.1)
Age at onset 8.5 (5.1–
10.8)
4.1 (2.2–8.7) 4.7 (1.9–9.3) 11.4 
(10–13.7)
11.6 
(8.1–13.3)
9.8 (7.6–11.5) 5 (2.5–11.5) 7.2 (2.8–
10.9)#
Disease duration 4 (1.4–7) 6.3 (3–9.8) 6 (2.6–9.5) 2.2 (1.9–3.8) 3.7 (2.7–5.5) 4.6 (3.4–7.6) 3 (1.5–4.6) 4.7 (2.5–8.4)#
ESR 5 (3–9) 7 (4–13) 7 (4–10) 16 (7–18) 8 (6–15) 8 (5–11) 6 (4–7) 7 (4–12)*
MD VAS 0 (0–0) 0 (0–2) 0 (0–1) 2.5 (0–4) 1 (0–4) 0.5 (0–2) 0 (0–1) 0 (0–2)*
No. of swollen 
joints
0 (0–0) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)*
No. of joints with 
pain
0 (0–0) 0 (0–1) 0 (0–3) 1 (0–2) 0 (0–2) 1 (0–2) 0 (0–0) 0 (0–2)*
No. of joints with 
LOM
0 (0–0) 0 (0–1) 0 (0–2) 1 (0–2) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–1)**
No. of active 
joints
0 (0–0) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–1)*
Active systemic 
features
2 (8.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (0.7%)
ANA status 0 (0%) 25 (23.6%) 9 (13.4%) 2 (11.8%) 2 (10.5%) 0 (0%) 0 (0%) 38 (12.5%)**
Uveitis 0 (0%) 11 (10.4%) 12 (17.9%) 0 (0%) 2 (10.5%) 4/38 (10.5%) 5 (16.1%) 34/301 
(11.3%)
PF total score 0.5 (0–6) 1 (0–4) 3 (0–6) 2 (0–3.5) 4 (1–9) 2 (0–5) 0 (0–2) 1 (0–5)* 0 (0–0)#
Pain VAS 1.5 (0–4.5) 2 (0–4.5) 3 (1–5) 1.5 (0.5–3.5) 3 (0.5–5) 1.5 (0.5–4) 1 (0–3) 2 (0–4.5) 0 (0–0)#
Disease activity 
VAS
1.5 (0–4.5) 1.5 (0–4) 2.5 (0.5–4.5) 1.5 (0.8–2) 3.5 (1.5–5.5) 1 (0.5–3.5) 1 (0–3) 2 (0–4)
Well-being VAS 1.5 (0–3) 1 (0–3.5) 2 (0.5–4) 1.8 (1–4) 2 (1.5–3.5) 2 (0.5–4) 1 (0–3) 1.5 (0.5–3.5)
HRQoL-PhH 3 (0–6) 2 (1–5) 4 (2–6) 2 (1–4.5) 6 (4–7) 3 (2–5) 2 (1–5) 3 (1–5) 0 (0–0)#
HRQoL-PsH 2 (0–5) 1 (0–4) 2 (0–4) 1 (0.5–2) 2 (2–4) 1 (0–4) 1 (0–3) 2 (0–4) 0 (0–0.5)#
HRQoL total 
score
5 (0–10) 4 (1–9) 6 (4–10) 3.5 (2–7) 9 (6–11) 6 (3–8) 4 (2–8) 5 (2–9) 0 (0–1)#
Pain/swell in > 1 
joint
8/22 (36.4%) 44/95 
(46.3%)
35/61 
(57.4%)
9/16 (56.3%) 8/13 (61.5%) 17/29 (58.6%) 11 (35.5%) 132/267 
(49.4%)
5/76 (6.6%)#
Morning stiff-
ness > 15 min
6/22 (27.3%) 30/95 
(31.6%)
22/61 
(36.1%)
4/16 (25%) 4/13 (30.8%) 11/29 (37.9%) 3 (9.7%) 80/267 (30%) 0 (0%)#
Subjective remis-
sion
12/22 
(54.5%)
54/95 
(56.8%)
43/61 
(70.5%)
11/16 
(68.8%)
11/13 
(84.6%)
18/29 (62.1%) 16 (51.6%) 165/267 
(61.8%)
In treatment 19/22 
(86.4%)
69/95 
(72.6%)
52/61 
(85.2%)
16/16 (100%) 12/13 
(92.3%)
28/29 (96.6%) 24 (77.4%) 220/267 
(82.4%)
Reporting side 
effects
7/19 (36.8%) 32/69 
(46.4%)
28/52 
(53.8%)
11/16 
(68.8%)
9/12 (75%) 9/28 (32.1%) 11/24 (45.8%) 107/220 
(48.6%)
Taking medica-
tion regularly
18/19 
(94.7%)
68/69 
(98.6%)
51/52 
(98.1%)
15/16 
(93.8%)
11/12 
(91.7%)
27/28 (96.4%) 23/24 (95.8%) 213/220 
(96.8%)
With problems 
attending 
school
6/17 (35.3%) 13/56 
(23.2%)
11/34 
(32.4%)
3/10 (30%) 4/7 (57.1%) 7/14 (50%) 1/13 (7.7%) 45/151 
(29.8%)
0 (0%)#
Satisfied with dis-
ease outcome
17/22 
(77.3%)
70/95 
(73.7%)
42/61 
(68.9%)
11/16 
(68.8%)
7/13 (53.8%) 20/29 (69%) 21 (67.7%) 188/267 
(70.4%)
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the PF items, with the exception of PF items 11 and 15, and 
for 90% of the HRQoL items, with the exception of item 1.
Item internal consistency (third Likert assumption)
Pearson’s item–scale correlations were ≥ 0.4 for 87% of 
items of the PF (except for PF items 11 and 15) and 100% 
of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.82 for PF-LL, 0.87 for PF-HW, 0.72 
for PF-US. Cronbach’s alpha was 0.84 for HRQoL-PhH and 
0.79 for HRQoL-PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 267/343 Child N = 76/357
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 84.3% 87.2%
 HRQoL-PhH 50.6% 58.9%
 HRQoL-PsH 61.8% 60.1%
 Pain VAS 25.1% 21.7%
 Disease activity VAS 25.1% 26.7%
 Well-being VAS 23.6% 29.4%
Ceiling effect, median
 PF 0.4% 0.0%
 HRQoL PhH 4.1% 3.1%
 HRQoL PsH 0.7% 1.6%
 Pain VAS 0.0% 0.4%
 Disease activity VAS 0.7% 0.8%
 Well-being VAS 0.7% 1.5%
Items with equivalent item–scale correlation 87% for PF, 90% for HRQoL 93% for PF, 80% for HRQoL
Items with item–scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 87% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.82 0.79
 PF-HW 0.87 0.75
 PF-US 0.72 0.74
 HRQoL-PhH 0.84 0.83
 HRQoL-PsH 0.79 0.78
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.92 0.92
 HRQoL-PhH 0.59 0.85
 HRQoL-PsH 0.81 0.63
Spearman’s correlation with JIA core set variables, median
 PF 0.3 0.4
 HRQoL-PhH 0.3 0.4
 HRQoL-PsH 0.2 0.3
 Pain VAS 0.3 0.3
 Disease activity VAS 0.3 0.2
 Well-being VAS 0.3 0.3
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Interscale correlation
The Pearson’s correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 19 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 7 days (1–18 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed 
an almost perfect reproducibility (ICC = 0.92). The ICC 
for the HRQoL-PhH showed a moderate reproducibility 
(ICC = 0.59), while the ICC for the HRQoL-PsH showed 
an almost perfect reproducibility (ICC = 0.81).
Convergent validity
The Spearman’s correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.1 to 
0.6 (median = 0.3). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.6, 
p < 0.001). The correlation of the PF total score with the ESR 
was not significant (p = 0.35). For the HRQoL, the median 
correlation of the PhH with the JIA core set of outcome vari-
ables ranged from − 0.04 to 0.8 (median = 0.3), whereas for 
the PsH ranged from − 0.1 to 0.6 (median = 0.2). The PhH 
showed the best correlation with the parent’s assessment of 
pain (r = 0.8, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.6, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centred and 
laboratory measures were 0.3 (0.1–0.5), 0.3 (0.1–0.4), and 
0.3 (0.1–0.5), respectively.
Discussion
In this study, the Danish version of the JAMAR was cross-
culturally adapted from the original standard English ver-
sion with two forward and two backward translations. 
According to the results of the validation analysis, the 
Danish parent and patient versions of the JAMAR pos-
sess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated 
well between patients with JIA and healthy controls. The 
PF total score proved to discriminate between the different 
JIA subtypes with children with psoriatic arthritis having 
a higher degree of disability.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: two PF items (stretch 
arms and bite a sandwich or an apple) showed a lower item’s 
internal consistency. However, the overall internal consist-
ency was excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were modest.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy-
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Danish version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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